Genetic Signatures Limited (GSS) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

We've changed the direction in which we're going. We've changed the focus in the products that we sell. We've changed some of the people and some of the roles to focus on the areas that we believe we need to focus on right now. And we're gonna go through that over the next few slides so you can really understand where we're gonna be and how I believe we are fit for the future. Here is our disclaimer, which you'll be pleased to know I will not read through. Just for those of you who don't know who we are, we are a molecular diagnostic company specializing in high throughput syndromic PCR testing for detecting infectious disease. Infectious disease is one of the biggest killers in the world. It's absolutely essential that we can diagnose earlier rather than later and nip that disease in the bud and stop it from spreading. The global burden for antimicrobial resistance is bigger than it's ever been. So with now having these syndromic tests to market that can help diagnose sooner, that can help the workflow in the laboratory, and that can make sure that patients get the right treatments at the right time, and not antibiotics if antibiotics are not necessary, is absolutely key. We develop and commercialize our high-throughput PCR tests powered by our proprietary 3Base technology, that streamlines DNA analysis for faster, more accurate results. We operate here in Australia. Our head office is here where we do all of our research, development and manufacturing. We have sales and field support teams in Australia, Europe and the United States. And we also work with channel partners across Europe and in Canada. I spoke about some highlights that I'm proud of, so I want to start with the first one. Our revenue grew, I would say, significantly at 63%, albeit off a small base, bu...